期刊文献+

骨转换生化标志物临床应用指南 被引量:17

Guidelines for clinical application of bone turnover biomarkers
原文传递
导出
摘要 骨转换对于防止骨骼疲劳损伤和维持机体矿物质平衡至关重要,骨转换失衡是多种骨骼疾病的关键病理生理机制。骨转换生化标志物(bone turnover markers,BTMs)是骨转换过程中产生的代谢产物或酶类,本指南介绍BTMs的测量方法、正常值及其在多种骨骼疾病的诊断与鉴别诊断、骨折风险预测、药物疗效评价等方面的重要作用。 Bone turnover plays important roles in preventing bone impairment and maintaining bone mineral balance.Bone turnover imbalance is the key pathophysiological mechanism of a variety of bone disorders.Bone turnover biomarkers(BTMs)include metabolites or enzymes produced in the process of bone turnover.This guide presents the measurement methods and normal ranges of BTMs,and its important values in the diagnosis and differential diagnosis of multiple bone diseases,prediction of bone fracture risk,and evaluation of the efficacy of anti-osteoporotic medicines.
作者 中华医学会骨质疏松和骨矿盐疾病分会 李梅 夏维波 章振林 谢忠建 刘建民 徐又佳 侯建明 陈德才 袁凌青 岳华 王鸥 姜艳 盛志峰 张浩 王覃 无;Li Mei;Xia Weibo;Zhang Zherdin(Chinese Society of Osteoporosis and Bone Mineral Research,Chinese Medical Association;Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China;Shanghai Clinical Research Center of Bone Diseases,Department of Osteoporosis and Bone Diseases,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China)
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2021年第10期863-874,共12页 Chinese Journal of Endocrinology and Metabolism
基金 国家重点研发计划项目(2018YFA0800801) 上海申康医院发展中心临床科技创新项目(SHDC12018120)。
关键词 骨转换 骨转换生化标志物 骨质疏松症 Bone turnover Bone turnover biomarkers Osteoporosis
  • 相关文献

参考文献7

二级参考文献82

  • 1刘红,廖二元,伍贤平,张红,罗湘杭,谢辉,曹行之,刘石平.正常女性与年龄相关的骨转换生化指标和骨密度的关系[J].中华内科杂志,2004,43(11):805-809. 被引量:27
  • 2邱明才,戴晨琳.代谢性骨病学[M].北京:人民卫生出版社,2012:9305.
  • 3Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. E- valuation, treatment, and prevention of vitamin D defi- ciency: an Endocrine Society clinical practice guideline [Jl- J Clin Endocrinol Metab, 2011, 96: 1911-1930.
  • 4Binkley N, Wiebe D. Clinical controversies in vitamin D: 25OHD measurement, target concentration, and supple- mentation [J]. J Clin Densitomet, 2013, 16: 402-408.
  • 5Xie Z, Zhang Z, Liao E, et al. High prevalence of vita- min D insufficiency and deficiency among postmenopausal women in China: Preliminary Results of a Chinese Multi- center Study [ C 1. The American Society for Bone and Mineral Research (ASBMR) Annual Meeting, 2014.
  • 6Wang Q, Lu C, Xu Y, et al. Prevalence of vitamin D de- ficiency in women who live with lowest sunshine: an epide- miological study in Sichuan, China [ C 1. 7th International Conference on Osteoporosis and Bone Research, 2014.
  • 7Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney Int, 2009, 113: $1-130.
  • 8Almond A, Ellis AR, Walker SW, et al. Current para- thyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease [ J]. Ann Clin Biochemist, 2012, 49: 63-67.
  • 9Liao E. FGF23 associated bone diseases [ J]. Front Med, 2013, 7: 65-80.
  • 10Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 meas- urements ~J~. J Clin Endocrinol Metab, 2012, 97: 3357-3365.

共引文献369

同被引文献165

引证文献17

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部